AMDA’s Statement on Aducanumab Approval

Angie Szumlinski Announcements

On June 24, 2021, The Society for Post-Acute and Long-Term Care Medicine posted a statement regarding the approval of dementia medication aducanumab. Below is a segment of their statement:

“The Society for Post-Acute and Long-Term Care Medicine is compelled to comment on the recent approval of the controversial parenteral Alzheimer’s Dementia (AD) medication, aducanumab. After considering the evidence, we conclude that the aducanumab trials did not adequately demonstrate safety or efficacy. Moreover, aducanumab has only been studied in individuals with mild cognitive impairment or early stage dementia due to hyperamyloidosis (e.g., AD) and has never been tested in a population representative of nursing home residents. We therefore cannot endorse recommending or prescribing aducanumab to post-acute and long-term care (PALTC) residents and patients.”

Please read the full AMDA Statement on Aducanumab to further understand their stance on this important issue.

Stay tuned, and stay well!